Skip to NavigationSkip to content

AstraZeneca to retire MedImmune brand amid restructuring

Published on 15/02/19 at 11:01am

AstraZeneca is retiring the MedImmune brand as part of a restructuring that will see biologics integrated into two new R&D units.

The announcement comes just a month after AstraZeneca announced organisational changes which will see the creation of therapy area specific R&D units.

AstraZeneca acquired MedImmune in 2007, running the firm as a separate biologics unit. However the restructuring will see the company integrated into AstraZeneca’s new R&D units.

The changes will not affect MedImmune’s ongoing partnerships and collaborations. AstraZeneca did not offer insight as to whether the restructuring would result in changes to management; however a spokesperson suggested that no layoffs are expected.

 The news comes after a number of high profile resignations. Nevertheless recent figures show that  AstraZeneca’s fourth quarter revenue jumped 11% year on year, reaching $6.4 billion

“As we recently entered a new phase in our strategic development, we have refined our organisation to position ourselves for the next phase of our journey,” CEO Pascal Soriot said.

Louis Goss

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches